#CANCERSM Chat topic 11-Jul-2019: Basics of Biomarker Testing

Until just a few years ago, chemotherapy was often the only option for some cancer patients.  In just a few short years, molecular therapies and immunotherapies have become commonplace as treatments for cancer patients.  But determining whether a particular cancer patient is a candidate for these new, often very expensive, molecular and immunotherapies requires molecular biomarker testing.  For many cancer patients and their families, the role of molecular biomarker testing in their diagnosis is a unfamiliar and confusing.  How is testing performed?  How is the test result analyzed? What is involved in… Read More

#LCSM Chat Topic 05/09/2019: What’s new in early stage lung cancer

Our May 9, 2019 #LCSM Chat at 8 pm Eastern (5 pm Pacific) will focus on the newest treatments for early stage lung cancer. The topic should be interesting to all who deal with early stage disease — patients, caregivers, oncology nurses, surgeons, radiologists, pulmonologists, pathologists, and oncologists. Although we have all heard about the tremendous advances in the treatment of metastatic lung cancer, we sometimes don’t appreciate the incredible progress we have also made in diagnosing and treating early stage lung cancer. Early stage patients can realistically strive for and expect… Read More

#LCSM Chat Topic 04/11/2019: Why research matters for lung cancer

It’s easy to understand the importance of lung cancer education and advocacy.  Of COURSE we should help patients and caregivers learn more about different types of lung cancer, biomarker testing, and treatment options.  Of course we should help them come together, to raise their voices, to make the general public understand the terrible toll lung cancer extracts from individuals and society, to combat stigma and nihilism. But what about research?  Some people suggest research isn’t as important as education or advocacy. They ask, “But what does research actually do for today’s patients?”… Read More